Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Fineline Cube Jun 16, 2026
Company Deals

Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution

Fineline Cube Jun 16, 2026
Company Deals

Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders

Fineline Cube Jun 16, 2026
Company Deals

TriApex Laboratories Files for Hong Kong IPO – Next-Generation CRO with 240+ NMPA Approvals

Fineline Cube Jun 16, 2026
Company Deals

Ningbo Sanxing Medical Electric Files HKEX Prospectus with Dual Business Model in Power Equipment and Rehabilitation Services

Fineline Cube Jun 15, 2026
Policy / Regulatory

China’s NHSA Receives Record 818 Drug Applications for 2026 National Reimbursement Drug List Adjustment

Fineline Cube Jun 15, 2026
Company Drug

BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis – First Selective TYK2 Inhibitor Expands China Indications

Fineline Cube Jun 16, 2026
Company Drug

Gilead Sciences Submits sNDA for Once-Weekly Oral Yeztugo PrEP – Potential First Long-Acting Oral HIV Prevention Option

Fineline Cube Jun 16, 2026
Company Drug

CanSino Biologics Initiates Phase Ib Study for Innovative Protein-Based Pneumococcal Vaccine

Fineline Cube Mar 13, 2023

China-based vaccines specialist CanSino Biologics Inc. has announced the initiation and first subject enrollment of...

Company Deals

Zenshine Pharmaceuticals Raises RMB 100 Million in Series B Financing for Drug Development

Fineline Cube Mar 13, 2023

China-based small molecule drug developer Nanjing Zenshine Pharmaceuticals Co., Ltd reportedly raised over RMB 100...

Company Deals

Livzon Pharmaceutical Secures Exclusive Rights to Onconic’s GERD Treatment Zastaprazan

Fineline Cube Mar 13, 2023

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced a licensing agreement with South Korean...

Company Drug

CStone’s Ayvakit Shows Significant Improvements in ISM at AAAAI Meeting

Fineline Cube Mar 13, 2023

China-based CStone Pharmaceuticals (HKG: 2616) announced that its US partner, Blueprint Medicines, published detailed data...

Company Medical Device

Lifetech’s IBS Angel Stent System Gains EU CE MDR Certification

Fineline Cube Mar 10, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received CE MDR certification...

Company Deals

Olipharma Secures Funding for Manufacturing Expansion in Pre-Series A+ Round

Fineline Cube Mar 10, 2023

Olipharma, a Contract Development and Manufacturing Organization (CDMO) specializing in small nucleic acid drugs and...

Company Drug

Inventiva and Chia Tai Tianqing’s Lanifibranor Advances with CDE Filing

Fineline Cube Mar 10, 2023

France-based Inventiva S.A. and China’s Chia Tai Tianqing have successfully filed a clinical trial application...

Company Drug

Simcere’s SIM0237 Begins Clinical Study for PD-L1 and IL-15 Targeting Bispecific Antibody

Fineline Cube Mar 10, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...

Deals Drug

AusperBio and Asymchem Form Strategic Partnership for Drug Development

Fineline Cube Mar 10, 2023

China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership...

Policy / Regulatory

NHSA’s 2022 Healthcare Security Bulletin Reveals Break-Even Performance

Fineline Cube Mar 10, 2023

The National Healthcare Security Administration (NHSA) has released its annual “Healthcare Security Development Statistical Bulletin”...

Company Drug

Bio-Thera Solutions Initiates Phase I Study for Trop2-Targeting ADC BAT8008

Fineline Cube Mar 10, 2023

China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced the first patient dosing in a multi-center,...

Company Drug

Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma

Fineline Cube Mar 10, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) and US biotech Seagen Inc. (Nasdaq: SGEN) have announced...

Company Deals

HuiLiao Biomedical Raises RMB 100 Million in Pre-Series A Round for mRNA Development

Fineline Cube Mar 10, 2023

China-based nucleic acid drug specialist Suzhou HuiLiao Biomedical Technology Co., Ltd has reportedly raised over...

Company Drug

InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China

Fineline Cube Mar 10, 2023

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...

Company Deals

Thederma Pharmaceuticals Raises RMB 100 Million for AhR-Targeted Therapies

Fineline Cube Mar 10, 2023

China-based Shanghai Thederma Pharmaceuticals Co., Ltd has reportedly raised RMB 100 million (USD 14.35 million)...

Company Deals

Xinrui Medtech Secures Pre-Series A Funding for Cardiovascular Device Development

Fineline Cube Mar 10, 2023

Xinrui Medtech, a cardiovascular device maker based in Suzhou, has reportedly raised “tens of millions”...

Company Medical Device

Lifetech Scientific’s IBS Angel Stent Receives CE MDR Certification in EU

Fineline Cube Mar 10, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received CE MDR certification...

Company Deals

Olipharma Raises Funds in Pre-Series A+ Round to Expand Manufacturing Facilities

Fineline Cube Mar 10, 2023

Olipharma, a small nucleic acid drug Contract Development and Manufacturing Organization (CDMO) based in Suzhou,...

Company Drug

Inventiva and Chia Tai Tianqing File Clinical Trial for Lanifibranor with CDE

Fineline Cube Mar 10, 2023

France-based Inventiva S.A. and China’s Chia Tai Tianqing have filed a clinical trial application with...

Company Drug

Simcere Pharmaceutical Initiates Clinical Study for Bispecific Antibody SIM0237 in Advanced Tumors

Fineline Cube Mar 10, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...

Posts pagination

1 … 570 571 572 … 684

Recent updates

  • BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis – First Selective TYK2 Inhibitor Expands China Indications
  • Lonza and Antharis Therapeutics Forge Exclusive ADC Partnership – Dual-Payload Platform Targets Gastrointestinal Cancers
  • AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035
  • Gilead Sciences Submits sNDA for Once-Weekly Oral Yeztugo PrEP – Potential First Long-Acting Oral HIV Prevention Option
  • Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis – First Selective TYK2 Inhibitor Expands China Indications

Others

Lonza and Antharis Therapeutics Forge Exclusive ADC Partnership – Dual-Payload Platform Targets Gastrointestinal Cancers

Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Company Drug

Gilead Sciences Submits sNDA for Once-Weekly Oral Yeztugo PrEP – Potential First Long-Acting Oral HIV Prevention Option

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.